Clinical Profile of Pediatric Patients with Steroid-resistant Nephrotic Syndrome Treated by Cyclophosphamide, Cyclosporin A, Mycophenolate Mofetile and Tacrolimus in Hasan Sadikin General Hospital

Ahmedz Widiasta; Muhammad Khalid Jambak; Nanan Sekarwana

doi:10.14710/dmj.v13i2.41983

DOI: https://doi.org/10.14710/dmj.v13i2.41983

Clinical Profile of Pediatric Patients with Steroid-resistant Nephrotic Syndrome Treated by Cyclophosphamide, Cyclosporin A, Mycophenolate Mofetile and Tacrolimus in Hasan Sadikin General Hospital

*Ahmedz Widiasta

- Nephrology Division, Child Health Department, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia, Indonesia

Muhammad Khalid Jambak - Nephrology Division, Child Health Department, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia, Indonesia

Nanan Sekarwana - Nephrology Division, Child Health Department, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia, Indonesia

BibTex Citation Data :

@article{dmj41983,
    author = {Ahmedz Widiasta and Muhammad Jambak and Nanan Sekarwana},
    title = {Clinical Profile of Pediatric Patients with Steroid-resistant Nephrotic Syndrome Treated by Cyclophosphamide, Cyclosporin A, Mycophenolate Mofetile and Tacrolimus in Hasan Sadikin General Hospital},
    journal = {Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)},
  volume = {13},
    number = {2},
    year = {2024},
    keywords = {Steroid-resistant nephrotic syndrome, laboratorium profile, remission, cyclophosphamide, cyclosporine, mycofenolate mofetil, tacrolimus, pediatric.},
    abstract = { Background: Steroid-resistant nephrotic syndrome is a major cause of chronic kidney disease in children and adolescents. These diseases require appropriate management, while in some developing countries; the availability of agents recommended by international guidelines is very limited. Research objectives: To determine and describe the patient profiles of pediatric Steroid Resistant Nephrotic Syndrome (SRNS) that use Cyclophosphamide (CPA), Cyclosporine(CyA), Tacrolimus, and Mycofenolat Mofetil (MMF) in Dr. Hasan Sadikin Hospital (RSHS), Bandung as a tertiary hospital in West Java, Indonesia. Methods and materials: This research used a retrospective study with crosssectional study design, total sampling method and medical record of pediatric (1-18 years old) patients from January 1 st  2017–September 31 st  2019 who were diagnosed as SRNS. Results : From 99 subjects that belonged to inclusion criteria, 35.4% pediatric SRNS patients were in the age group 6-10 years and 60.6% were males. Laboratorium profiles showed among all population, ureum <100 mg/dL were found as high as 97%, creatinine 0.3-1.0 mg/dL (71.7%) albumin >2,5 gr/dL (51.5%), negative hematuria (68.7%) , protein dipstick < 3 (50.5%), and LFG > 90 mL/min/1.73 m 2  (79.8%).. The patients generally had use CPA (87.9%) and remission <6 month (51.5%). Conclusion: Profiles of pediatric patients are important to diagnose and prognose SRNS. By using these approaches, it is feasible to access and detect the most effective treatment for SRNS. },
   issn = {2540-8844},   pages = {78--82}  doi = {10.14710/dmj.v13i2.41983},
    url = {https://ejournal3.undip.ac.id/index.php/medico/article/view/41983}
}

Citation Format:

Abstract

Background: Steroid-resistant nephrotic syndrome is a major cause of chronic kidney disease in children and adolescents. These diseases require appropriate management, while in some developing countries; the availability of agents recommended by international guidelines is very limited. Research objectives: To determine and describe the patient profiles of pediatric Steroid Resistant Nephrotic Syndrome (SRNS) that use Cyclophosphamide (CPA), Cyclosporine(CyA), Tacrolimus, and Mycofenolat Mofetil (MMF) in Dr. Hasan Sadikin Hospital (RSHS), Bandung as a tertiary hospital in West Java, Indonesia. Methods and materials: This research used a retrospective study with crosssectional study design, total sampling method and medical record of pediatric (1-18 years old) patients from January 1st 2017–September 31st 2019 who were diagnosed as SRNS. Results : From 99 subjects that belonged to inclusion criteria, 35.4% pediatric SRNS patients were in the age group 6-10 years and 60.6% were males. Laboratorium profiles showed among all population, ureum <100 mg/dL were found as high as 97%, creatinine 0.3-1.0 mg/dL (71.7%) albumin >2,5 gr/dL (51.5%), negative hematuria (68.7%) , protein dipstick < 3 (50.5%), and LFG > 90 mL/min/1.73 m2 (79.8%).. The patients generally had use CPA (87.9%) and remission <6 month (51.5%). Conclusion: Profiles of pediatric patients are important to diagnose and prognose SRNS. By using these approaches, it is feasible to access and detect the most effective treatment for SRNS.

Note: This article has supplementary file(s).

Fulltext View|Download | Research Instrument

Untitled

Subject
Type	Research Instrument
	Download (16KB) Indexing metadata

Research Instrument

Untitled

Subject
Type	Research Instrument
	Download (29KB) Indexing metadata

Keywords: Steroid-resistant nephrotic syndrome, laboratorium profile, remission, cyclophosphamide, cyclosporine, mycofenolate mofetil, tacrolimus, pediatric.

Funding: -

Article Metrics:

Article Info

Section: Original Articles

Language : EN

In Vol 13, No 2 (2024): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)

Recent articles

Association Between Immune-Inflammation Index (SII) and Ferritin with Hepatic Function in Patients with Thalassemia Major The Effect Of Sensory-Motor Virtual Reality on Balance in Children with Clinical Down Syndrome Effects of Garcinia Mangostana Linn Pericarp Extract and Physical Exercise on Atheroembolic Histopathologic Features Kidney in Wistar Rats with Metabolic Syndrome Case Report: Successful Management of Ischemic Stroke Patients with Pneumonia, Diabetes Mellitus, and Hypertension in The ICU Case Report: Diagnosis and Management of Body Stalk Anomaly More recent articles

Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–39
Clark AG. Steroid-responsive nephrotic syndrome. Pediatr Nephrol. 1999;
Lombel RM, Gipson DS, Hodson EM. Treatment of steroid-sensitive nephrotic syndrome: New guidelines from KDIGO. Pediatr Nephrol. 2013;28(3):415–26
MacHardy N, Miles P V., Massengill SF, Smoyer WE, Mahan JD, Greenbaum L, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2193–201
Abrantes MM, Cardoso LSB, Lima EM, Silva JMP, Diniz JS, Bambirra EA, et al. Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis. Pediatr Nephrol. 2006;21(7):1003–12
Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: A systematic review. Health Technol Assess (Rockv). 2007;11(21)
Lombel RM, Hodson EM, Gipson DS. Treatment of steroid-resistant nephrotic syndrome in children: New guidelines from KDIGO. Pediatr Nephrol. 2013;28(3):409–14
Silverstein DM, Matti Vehaskari V, Symons JM, Alon US, Straatmann C. Steroid-Resistant Nephrotic Syndrome. Pediatr Nephrol. 2012;369–402
Alatas H, Trihono PP. Pengobatan Terkini Sindrom Nefrotik (SN) pada Anak. Sari Pediatr. 2016;17(2):155
Barletta G-M, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18(8):833–7
Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, et al. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25(5):883–8
Hidayati EL, Pardede SO, Trihono PP. Comparison of oral and intravenous cyclophosphamide in children with steroid-resistant nephrotic syndrome. Paediatr Indones. 2011;51(5):266–71
Subandiyah K. The outcome of nephrotic syndrome in children-prospective population based cohort study. J Kedokt Brawijaya. 2004;20(3):147–51
Wati KDK, Suarta K, Soetjiningsih S. Tinggi Badan dan Usia Tulang Sindrom Nefrotik yang Mendapat Terapi Steroid Jangka Panjang. Sari Pediatr. 2016;4(2):83
Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2004;19(5):494–8
Haycock G. The child with idiopathic nephrotic syndrome. Clin Paediatr Nephrolgy. 2003;341–66
Wang C shi, Greenbaum LA. Nephrotic Syndrome. Pediatr Clin North Am [Internet]. 2019;66(1):73–85. Available from: https://doi.org/10.1016/j.pcl.2018.08.006
Obeidová H, Merta M, Reiterová J, Maixnerová D, Stekrová J, Rysavá R, et al. Genetic basis of nephrotic syndrome—review. Prague Med Rep. 2006;107(1):5–16
Woodroffe R al, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. In: NIHR Health Technology Assessment programme: Executive Summaries. NIHR Journals Library; 2005
Otukesh H, Otukesh S, Mojtahedzadeh M, Hoseini R, Fereshtehnejad S, Fard AR, et al. IJKD H Otukesh management and outcome of SRNS in children.pdf. 2009;3(4):210–7
Antignac C. Genetic models: clues for understanding the pathogenesis of idiopathic nephrotic syndrome. J Clin Invest. 2002;109(4):447–9
Alatas H, Tambunan T, Trihono PP, Pardede SO. Konsensus tata laksana sindrom nefrotik idiopatik pada anak. Jakarta UKK Nefrol IDAI. 2005;1–17
Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid-resistant nephrotic syndrome: a controlled study. Am J Dis Child. 1988;142(9):985–8

Last update:

No citation recorded.

Last update:

No citation recorded.

Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC-BY-NC-SA) that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal. - Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).